Evidence map›Paper›PMID 35493497›Full record

ReviewFrontiers in immunology2022

Marie-Sophie Meuleman, Anna Duval, Véronique Fremeaux-Bacchi, Lubka T Roumenina, Sophie Chauvet

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Locally generated C3 regulates the clearance ofFrontiers in microbiology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Marie-Sophie MeulemanCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Anna DuvalCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Véronique Fremeaux-BacchiCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Lubka T RoumeninaCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Sophie ChauvetCentre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Centre de Recherche des Cordeliers · FRInserm · FRSorbonne Université · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As part of the innate immune system, the complement system plays a key role in defense against pathogens and in host cell homeostasis. This enzymatic cascade is rapidly triggered in the presence of activating surfaces. Physiologically, it is tightly regulated on host cells to avoid uncontrolled activation and self-damage. In cases of abnormal complement dysregulation/overactivation, the endothelium is one of the primary targets. Complement has gained momentum as a research interest in the last decade because its dysregulation has been implicated in the pathophysiology of many human diseases. Thus, it appears to be a promising candidate for therapeutic intervention. However, detecting abnormal complement activation is challenging. In many pathological conditions, complement activation occurs locally in tissues. Standard routine exploration of the plasma concentration of the complement components shows values in the normal range. The available tests to demonstrate such dysregulation with diagnostic, prognostic, and therapeutic implications are limited. There is a real need to develop tools to demonstrate the implications of complement in diseases and to explore the complex interplay between complement activation and regulation on human cells. The analysis of complement deposits on cultured endothelial cells incubated with pathologic human serum holds promise as a reference assay. This

Indexed as

Atypical Hemolytic Uremic SyndromeEndothelial CellsComplement ActivationComplement System ProteinsEndotheliumFemaleHumansMalePregnancyComplement System Proteinscomplementdiagnosticsendothelial cellsexplorationskidney injurynephrologyprognosticstherapeutics

Identifiers

PMID35493497
PMCPMC9041553
OpenAlexW4223426982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.